Source: Eur Respir J 2003; 22: 263-267
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Brand P., Beckmann H., Maas Enriquez M., Meyer T., Mullinger B., Sommerer K., Weber N., Weuthen T., Scheuch G.. Peripheral deposition of α1-protease inhibitor using commercial inhalation devices. Eur Respir J 2003; 22: 263-267

Member's Comments

No comment yet.

Related content which might interest you: Effective and efficient nebulization of alpha1-proteinase inhibitor (alpha1-PI) for inhalation therapy using the AKITA2® APIXNEBÔ nebulizer system Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 What the pulmonary specialist should know about the new inhalation therapies Source: Eur Respir J 2011; 37: 1308-1417 Year: 2011 Chronic inhalation toxicity study of nebulized alpha1 proteinase inhibitor (alpha1-PI), TAL6005, in rodents Source: Annual Congress 2010 - Models of airways disease Year: 2010 Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation Source: Eur Respir J 2011; 38: 1328-1335 Year: 2011 Fast, efficient and realistic in vitro delivery of inhaled drugs to pulmonary cells: Application to the proteasome inhibitor bortezomib Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013 SPARTA: Efficacy and safety assessment of two regimens of alpha1-proteinase inhibitor in emphysema due to alpha1-antitrypsin deficiency Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Single and repeated dose inhalation toxicology studies with alpha-1 proteinase inhibitor TAL6005 Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008 Efficient deposition and sustained lung concentrations of NVA237 after inhalation via the Breezhaler® device in man Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency Source: Eur Respir J 2009; 33: 354-360 Year: 2009 Lung deposition of an aerosol produced by a new inhalation device for ventilated patients Source: Eur Respir J 2005; 26: Suppl. 49, 88s Year: 2005 Effects of 5-lipoxygenase inhibitor on airway responses to inhaled organic dust in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 307s Year: 2002 LATE-BREAKING ABSTRACT: Anti-inflammatory effect of a novel inhaled dual PDE3/4 inhibitor RPL554 in man, a unique “first-in-class” drug for the treatment of COPD & asthma Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013 Safety, immunogenicity and pharmacokinetics (PK) of a 120 mg/kg/week dose of alpha1-proteinase inhibitor in alpha1-antitrypsin deficiency Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 LATE-BREAKING ABSTRACT: Effect of inhalation profiles and throat geometries on predicted lung deposition of budesonide and formoterol (BF) when inhaled through two different devices Source: International Congress 2014 – Innovative technology and techniques in respiratory function Year: 2014 Inhaled therapies: plastics, propellants, and pollutants Source: Virtual Congress 2021 – Environment, air pollution, health and respiratory disease Year: 2021 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Expanding role of aerosols: systemic drug delivery, gene therapy and vaccination Source: Annual Congress 2007 - ISAM - Expanding role of aerosols: systemic drug delivery, gene therapy and vaccination Year: 2007 Determination of tissue concentrations of metabolites in surgical preparations following inhalation of beclomethasone-dipropionate using conventional and extrafine aerosols Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003 LATE-BREAKING ABSTRACT: Effect of inhaled kinase inhibitor on airway inflammation assessed in induced sputum after challenge with inhaled lipopolysaccharide Source: International Congress 2016 – Novel mechanisms and therapeutic targets in acute and chronic inflammatory disease Year: 2016 RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016